| case report | Q2782326 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1013263520 |
| P356 | DOI | 10.1186/1477-7819-10-235 |
| P932 | PMC publication ID | 3542167 |
| P698 | PubMed publication ID | 23134665 |
| P5875 | ResearchGate publication ID | 233328396 |
| P2093 | author name string | Ying Yuan | |
| Hong Shen | |||
| Shenglin Ma | |||
| Yinghong Hu | |||
| Chunwen Tan | |||
| Modan Li | |||
| Xuefeng Fang | |||
| P2860 | cites work | Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers | Q29615475 |
| Activity of pemetrexed against brain metastases in a patient with adenocarcinoma of the lung | Q33431633 | ||
| Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer | Q34557318 | ||
| Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib | Q34566991 | ||
| Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm | Q34632917 | ||
| Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer | Q37274280 | ||
| High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer | Q37681047 | ||
| Personalized Medicine in Non–Small-Cell Lung Cancer: Is KRAS a Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor–Targeted Therapy? | Q37797818 | ||
| De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer | Q38417668 | ||
| Pemetrexed and cisplatin with concurrent radiotherapy for locally advanced non-small cell and limited disease small cell lung cancer: results from 2 phase I studies | Q43185507 | ||
| Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). | Q44519250 | ||
| Gefitinib as a first line of therapy in non-small cell lung cancer with brain metastases | Q45093737 | ||
| Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer | Q45098702 | ||
| Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer. | Q45919728 | ||
| Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population | Q46193107 | ||
| Efficacy of platinum-based chemotherapy after cranial radiation in patients with brain metastasis from non-small cell lung cancer | Q46535764 | ||
| Gefitinib is also active for carcinomatous meningitis in NSCLC. | Q46604361 | ||
| Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain | Q48203077 | ||
| Intracarotid low dose bradykinin infusion selectively increases tumor permeability through activation of bradykinin B2 receptors in malignant gliomas | Q48443469 | ||
| The prognostic factors of lung cancer patients with brain metastases treated with radiotherapy | Q48496818 | ||
| Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01) | Q83411205 | ||
| P304 | page(s) | 235 | |
| P577 | publication date | 2012-11-07 | |
| P1433 | published in | World Journal of Surgical Oncology | Q14520241 |
| P1476 | title | Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib | |
| P478 | volume | 10 |
| Q46354602 | A case report of patient with advanced non-small cell lung cancer by five times EGFR-TKIs therapy |
| Q26781690 | Diagnosis and Treatment of Leptomeningeal Metastasis in Non-small Cell Lung Cancer |
| Q38971627 | Experimental Treatments for Leptomeningeal Metastases From Solid Malignancies |
| Q47133535 | Leptomeningeal Disease and the Evolving Role of Molecular Targeted Therapy and Immunotherapy |
| Q31121041 | Pemetrexed/cisplatin as first-line chemotherapy for advanced lung cancer with brain metastases: A case report and literature review |
| Q37368787 | Phase II clinical trial of whole-brain irradiation plus three-dimensional conformal boost with concurrent topotecan for brain metastases from lung cancer |
| Q37108253 | Quick regression of brain metastases from lung adenocarcinoma with epidermal growth factor receptor-tyrosine kinase inhibitor treatment: A case report and literature review |
| Q49894049 | Targeted therapy for leptomeningeal metastases in non-small cell lung cancer - Changing treatment paradigms |
| Q26740529 | The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer |
| Q55504755 | [Research progress of lung cancer with leptomeningeal metastasis]. |
Search more.